ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

Clinical trial NCT04049513 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04049513
Sponsor: Malaghan Institute of Medical Research
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphomas Non-Hodgkin's B-Cell Diffuse Large B-cell Lymphoma (DLBCL)Primary Mediastinal B-cell Lymphoma (PMBCL)Transformed Follicular Lymphoma (TFL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)

Start date: 2019-10-11
Primary completion: 2024-06-12
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.